GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-30
Target enrollment:
Participant gender:
Summary
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent nasopharyngeal carcinoma.